Equillium Inc (EQ)

Currency in USD
1.060
-0.060(-5.36%)
Closed·
1.020-0.040(-3.77%)
·
EQ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.0551.170
52 wk Range
0.8123.540
Key Statistics
Prev. Close
1.06
Open
1.12
Day's Range
1.055-1.17
52 wk Range
0.812-3.54
Volume
570.78K
Average Volume (3m)
544.94K
1-Year Change
10.4167%
Book Value / Share
0.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.556
Upside
+707.13%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Equillium Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.556
(+707.13% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Raymond James
Buy7.00+560.38%-MaintainNov 13, 2026
Jefferies
Buy4.00+277.36%-MaintainNov 13, 2026
Leerink
Buy6.00+466.04%-New CoverageOct 12, 2026
Piper Sandler
Buy20.00+1,786.79%-MaintainOct 06, 2026
Clear Street
Buy9.00+749.06%-New CoverageJul 21, 2026

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
-0.04 / -0.05
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EQ Income Statement

Compare EQ to Peers and Sector

Metrics to compare
EQ
Peers
Sector
Relationship
P/E Ratio
−4.8x36.0x−0.2x
PEG Ratio
−0.070.190.00
Price/Book
1.7x12.0x2.6x
Price / LTM Sales
-15.4x2.6x
Upside (Analyst Target)
-70.1%76.9%
Fair Value Upside
Unlock−9.6%14.9%Unlock

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.56M8.38%7.22M
Other Institutional Investors
52.96M67.58%58.25M
Public Companies & Retail Investors
18.84M24.05%20.73M
Total
78.37M100.00%86.2M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group Ltd.8.29%6,494,5717,144
Aberdeen Group Plc5.69%4,458,3514,904

People Also Watch

7.590
CAPR
+0.80%
88.91
ANT
-8.50%
0.3900
OTLK
-2.74%
8.80
OWL
-2.33%
8.600
STRO
-1.38%

FAQ

What Is the Equillium (EQ) Stock Price Today?

The Equillium stock price today is 1.060 USD.

What Stock Exchange Does Equillium Trade On?

Equillium is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Equillium?

The stock symbol for Equillium is "EQ."

What Is the Equillium (EQ) Afterhours Price Today? (Afterhours variable test: 1.020) Current Date: Nov 21, 2026

After hours price: 1.020. After hours price change (units): -0.040. Price change percentage: -3.770%

What Is the Equillium Market Cap?

As of today, Equillium market cap is 92.200M USD.

What Is Equillium's Earnings Per Share (TTM)?

The Equillium EPS (TTM) is -0.18.

When Is the Next Equillium Earnings Date?

Equillium will release its next earnings report on Mar 24, 2027.

From a Technical Analysis Perspective, Is EQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Equillium Stock Split?

Equillium has split 1 times.

How Many Employees Does Equillium Have?

Equillium has 15 employees.

What is the current trading status of Equillium (EQ)?

As of Nov 21, 2026, Equillium (EQ) is trading at a price of 1.060 USD, with a previous close of 1.060 USD. The stock has fluctuated within a day range of 1.055 USD to 1.170 USD, while its 52-week range spans from 0.812 USD to 3.540 USD.

What Is Equillium (EQ) Price Target According to Analysts?

The average 12-month price target for Equillium is 8.556 USD, with a high estimate of 20 USD and a low estimate of 4 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +707.13% Upside potential.

What Is the EQ Premarket Price?

EQ's last pre-market stock price is 1.110 USD. The pre-market share volume is 40.000, and the stock has decreased by -0.010, or -0.890%.

What Is the EQ After Hours Price?

EQ's last after hours stock price is 1.020 USD, the stock has decreased by -0.040, or -3.770%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.